Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
 
Survey
We asked 40 leaders, What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients 19%
Restricts innovation and the development of new drugs 51%
Has no impact on drug development 1%
Don’t Know 19%

Talk to us:
jupton@advanstar.com

Advertise with us:
wblow@advanstar.com

10 June, 2014
Surviving the Emerging Market Price Wars
How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment...Read more
Immunotherapies: The New Hope for Cancer Treatment
The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey ... Read more
The Urge to Merge: Deal-Making Lessons from History
The rationale for pharmaceutical industry merger activity over the past two decades has been the perceived need for increased economies of scale, improved R&D productivity, access to new technologies or geographies, and increased exposure to patent loss and generic competition. However, developing and rapidly ramping up new drugs to replace the lost revenue—particularly in the US—has proven difficult, writes Cliff Kalb ... Read more
Sanofi Responds to UK’s Value-Based Assessment Plans
The UK’s National Institute for Health and Care Excellence set out their proposals for value-based assessment (VBA) in March 2014. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 approaches. But Sanofi have gone further than some in sharing their thinking early ... Read more
Product Cycle Strategies for Greater Profitability
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics allowing companies to align their strategies around the push for greater profitability, putting them on the right track ... Read more
Also in this issue
Investment in Pharma Sales “Flat” in 2013
EFPIA: Pharma Should be at the Heart of Economic Reform
Rise in IPOs Eases Pharma’s Investment Woes
Pharm Exec eBooks Available as Apps